Acquisition Announced
Otsuka acquisition of Transcend Therapeutics
US$700m consideration
Announced Mar 2026
Advisers
Transcend Therapeutics
Target
- Financial adviser
- Legal adviser
Otsuka
Acquirer
- Legal adviser
- Target
- Transcend Therapeutics
- Acquirer
- Otsuka
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma, Behavioral Health
In the league tables
Similar deals
- Teva Pharmaceuticals acquisition of Emalex Biosciences Apr 2026 · US$700m · Pharma
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Transcend on its sale to Otsuka centerviewpartners.com
- Mar 2026 Kirkland Advises Transcend Therapeutics on Sale to Otsuka kirkland.com
- Mar 2026 Otsuka Pharmaceutical to Acquire Transcend Therapeutics skadden.com
- 30 Mar 2026 Goodwin Advises Transcend Therapeutics on IP Aspects of its Acquisition by Otsuka Pharmaceutical for Up to $1.225 Billion goodwinlaw.com



